EU clinical trials decline 13.5% as academic sponsors pull back

OMB has opened a request for information on domestic and near shore manufacturing of the ASPR 86 essential medicines. Manufacturers have until 26 October 2026 to declare idle capacity, set out new plant plans, and name the unit price they need to stay viable. #SyenzaNews #MarketAccess #pharmaceuticalmanufacturing

Portugal cancer drug delays average 926 days from EU approval, against 655 days across the EU. The figures on the oncology patient journey also show 50.8% of patients have gone without medication at least once, and two of the country’s three screening programmes remain below the 90% coverage target. #SyenzaNews #oncology #MarketAccess #healthpolicy

The Bureau of Industry and Security has named nine product classes and 19 jurisdictions that can ship specialty medicines into the United States at a zero tariff, while the 100 percent Section 232 duty reaches most patented pharmaceuticals on 29 September 2026. Companies arguing an urgent U.S. health need now have a defined route to apply. #SyenzaNews #MarketAccess #PharmaceuticalTariffs

Zorginstituut Nederland has ruled that the Inreda AP stays out of the Dutch basic package. The DARE trial found no clinically relevant gain in glucose control or quality of life, serious adverse events were about three times more common, and half of the patients stopped using the device. #SyenzaNews #MedTech #MarketAccess #HealthEconomics

Eli Lilly and Company has set a parity target for its diabetes and obesity medicines: treat as many people in low- and middle-income countries as in high-income countries by 2040. The commitment carries no price mechanism, so progress will be judged against Lilly’s own annual Sustainability Report. #SyenzaNews #globalhealth #pharmaceuticals #MarketAccess

A National Press Foundation briefing on drug prices and workforce shortages: separate list price from net price, ask which goal a policy serves, and check whether more clinicians really mean more appointments. #SyenzaNews #HealthEconomics #MarketAccess

Germany drug pricing policies are now the subject of a US Section 301 investigation. AbbVie’s chief counsel, Perry Siatis, has filed written evidence and testified that government price setting, mandatory rebates and reimbursement restrictions undercut the incentives that fund new medicines. He also cites a German-French working group on keeping innovative medicines available. #SyenzaNews #MarketAccess #DrugPricing #HEOR

A randomized trial in 268 men awaiting radical prostatectomy found AI preoperative communication cut GAD-7 anxiety scores and nearly halved surgeon consultation time. The AI answered 2,847 of 3,507 patient questions. #SyenzaAI #SyenzaNews #MarketAccess #ProstateCancer #AIinHealthcare

Mounjaro passed €1 million in pharmacy sales in a single day in Portugal, on more than 3,000 packs, and the Ordem dos Médicos has asked Infarmed for prescription data. Here is what the numbers show on access, reimbursement and supply. #SyenzaNews #GLP1 #MarketAccess

New OHE research puts the economic burden of obesity in eight European countries at 0.7% to 1.4% of GDP. Germany carries the largest bill at EUR 55.2bn; the UK carries the largest productivity share at 58%. #SyenzaAI #SyenzaNews #MarketAccess #HealthEconomics #Obesity